Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
pharmaceutical investing Vertex Announces Northern Ireland Offer Accepted for Cystic Fibrosis Treatments
Health Canada Approves PrSYMDEKO (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis
Oreterra Geological Staff Mobilize to Trek South Copper-Gold Prospect, Golden Triangle, BC, to Prepare for Maiden Drill Program
